-
Media Release
New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer
-
Media Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Media Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Media Release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
-
Media Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Media Release
NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"
-
Story
Building for the Future: Novartis Expands Manufacturing Hub in North Carolina -
Media Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Media Release
Novartis and US government reach agreement on lowering drug prices in the US
-
Media Release
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
-
Media Release
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
-
Story
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future